NTX-301 + Temozolomide
High-grade Glioma (IDH1 mutated or Wild-Type)
Phase 1/2 (Planned Cohort)Not Yet Activated
Key Facts
Indication
High-grade Glioma (IDH1 mutated or Wild-Type)
Phase
Phase 1/2 (Planned Cohort)
Status
Not Yet Activated
Company
About Xennials Therapeutics
Xennials Therapeutics is a private, pre-revenue biotech leveraging a proprietary nanoparticle-based drug delivery platform to develop novel oncology therapeutics. Its lead asset, NTX-301 (a DNMT1 inhibitor), is in a Phase 1/2 study for various solid tumors, exploring monotherapy and combinations. The company emphasizes a strategy of coupling novel anti-cancer assets with its targeted delivery technology to address significant unmet needs in oncology treatment paradigms.
View full company profile